• 1979—Northwestern University, BA
• 1984—Duke University School of Medicine, MD

Postgraduate Training

• 1985-87—Surgery Internship, Brigham and Women’s Hospital
• 1987-91—Urology Residency, Harvard Program in Urology
• 1991-93—Fellowship, Beth Israel Hospital and Whitehead Institute of Biomedical Research

Academic Positions

• 1985-91—Fellow, Surgery, Harvard Medical School
• 1991-97—Instructor, Surgery, Harvard Medical School
• 1991-93—Associate in Surgery (Urology), Brigham and Women's Hospital
• 1991-93—Consultant Urologist, West Roxbury Veteran’s Administration Hospital
• 1991-97—Assistant Urologist, Harvard University Health Services
• 1993-96—Associate in Surgery (Urology), Beth Isreal Hospital
• 1996-00—Associate in Surgery (Urology), Beth Isreal Deaconess Medical Center
• 1997-00—Consultant Urologist, Harvard University Health Services
• 1997-00—Assistant Professor, Surgery, Harvard Medical School
• 2000-05—Associate Professor, University of Iowa Department of Urology
• 2005—Professor, University of Iowa Department of Urology

Affiliations and Offices Held

• American Urological Association
• American Association for Cancer Research
• American Society for Microbiology
• Society for Basic Urologic Research
• American College of Surgeons
• Iowa Urological Society
• 1993-00—Director, Urologic Laparoscopic Surgery, Beth Israel Hospital
• 1998-00—Member, Beth Israel Deaconess Cancer Center
• 1999-00—Director, Beth Israel Deaconess Medical Center Bladder Cancer Center
• 2000—Member, Holden Comprehensive Cancer Center
• 2005-07—National Board Member, Society for Basic Urologic Research

Honors

• Fulbright/German Academic Exchange Service, Foreign Study Scholar
• Alpha Omega Alpha, Duke University
• American Foundation for Urologic Disease Scholar
• Edwin Beer Foundation Research Award
• Who's Who in Medical Sciences Education
• America's Top Cancer Doctors, 2005
• America's Top Doctors, 2003-2005

Research and Clinical Interests

• Development of recombinant BCG for bladder cancer immunotherapy (U.S. patents, 1997, 1999)
• Mechanism of anti-cancer action of BCG and cytokines
• Role of FAS in mediating cancer apoptosis
• Use of phage display peptides for bladder cancer targeting